-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Finishingrainbow
On May 26, 2021, AstraZeneca China announced that it has obtained the anti-tumor biopharmaceutical Boyouno (bevacizumab injection) from Boan Biologics, a subsidiary of Luye Pharmaceutical Group, in 21 provinces, cities, and autonomous regions in mainland China.
According to the cooperation content, this cooperation with AstraZeneca is mainly responsible for promoting the expansion of bevacizumab injection to the domestic county market.
In fact, the grassroots county market is an area where AstraZeneca has continued to exert its strength in recent years.
It is worth noting that this cooperation is not the first domestic market promotion right that AstraZeneca won in the first half of this year.
On February 28, AstraZeneca won the right to promote Junshi Biologics anti-PD-1 monoclonal antibody Tuoyi® (Treprizumab injection) in non-core markets in mainland China, and the subsequent approval for listing The exclusive right to promote urothelial cancer indications nationwide.
It is reported that Wang Lei, AstraZeneca’s global executive vice president, had previously benchmarked AstraZeneca against Alibaba, saying that he would implement 200 products in China, including self-research, joint development, agency, and investment.
For these 200 products, some media disassembled them into: 50 self-developed products + 50 first-class new drugs developed in cooperation with China + 50 agent products + 50 diagnostic device products.
And this year has not passed halfway, AstraZeneca has frequently made big moves.
